ONMD OneMedNet Corp
Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1849380 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY365.1%
TTM net income YoY-412.3%
TTM EPS YoY-14,000.0%
Revenue 3-yr CAGR33.7%
Net income 3-yr CAGR—
Margins
Gross margin-49.7%
Operating margin-440.0%
Net margin-452.9%
FCF margin-285.4%
EBITDA margin-438.6%
Returns
ROE—
ROA-506.7%
ROIC (approx.)—
Asset turnover1.12x
Leverage & solvency
Liabilities / assets277.5%
Debt / equity—
Current ratio0.38x
Interest coverage-289.40x
Cash quality & payout
Operating cash flow / net income0.63x
Accruals ratio-188.2%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.02M | $292,000 | $96,000 | $891,000 | $177,000 | $155,000 | $137,000 | $26,000 |
| Cost of revenue | $1.39M | $857,000 | $476,000 | $726,000 | $399,000 | $396,000 | $361,000 | $52,000 |
| Gross profit | -$363,000 | -$565,000 | -$380,000 | $165,000 | -$222,000 | -$241,000 | -$224,000 | -$26,000 |
| R&D expense | $424,000 | $324,000 | $311,000 | $443,000 | $323,000 | $382,000 | $348,000 | $340,000 |
| SG&A expense | $1.19M | $981,000 | $1.48M | $2.38M | $1.39M | $1.18M | $1.36M | $2.09M |
| Operating income | -$2.23M | -$2.26M | -$2.55M | -$3.08M | -$2.23M | -$2.06M | -$2.22M | -$2.67M |
| Interest expense | $8,000 | $9,000 | $10,000 | $8,000 | $6,000 | $22,000 | $31,000 | $92,000 |
| Net income | -$2.66M | -$2.17M | -$2.45M | -$3.14M | -$741,000 | $2.98M | -$1.90M | -$2.37M |
| EBITDA | -$2.23M | -$2.26M | -$2.54M | -$3.07M | -$2.23M | -$2.03M | -$2.21M | -$2.64M |
| EPS (basic) | -0.43 | -0.04 | -0.04 | — | -0.14 | 0.07 | -0.06 | — |
| EPS (diluted) | -0.43 | -0.04 | -0.04 | — | -0.14 | 0.07 | -0.06 | — |
| Weighted avg. shares (diluted) | 6.15M | 58.02M | 55.32M | — | 5.26M | 38.41M | 34.10M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $137,000 | $358,000 | $233,000 | $585,000 | $149,000 | $122,000 | $144,000 | $172,000 |
| Receivables | $2.27M | $664,000 | $697,000 | $495,000 | $582,000 | $254,000 | $247,000 | $213,000 |
| Current assets | $2.56M | $1.31M | $1.46M | $2.10M | $1.45M | $2.27M | $1.63M | $3.62M |
| PP&E, net | $44,000 | $51,000 | $47,000 | $56,000 | $60,000 | $70,000 | $101,000 | $108,000 |
| Total assets | $2.61M | $1.36M | $1.51M | $2.15M | $1.51M | $2.34M | $1.73M | $3.73M |
| Current liabilities | $6.70M | $4.73M | $5.36M | $4.83M | $5.00M | $6.16M | $18.15M | $19.23M |
| Short-term debt | $563,000 | $701,000 | $837,000 | $974,000 | — | — | $2.33M | $9.38M |
| Long-term debt | $99,000 | $132,000 | $176,000 | $220,000 | — | — | $2.33M | $2.32M |
| Total debt | $662,000 | $833,000 | $1.01M | $1.19M | — | — | $4.66M | $11.70M |
| Total liabilities | $7.24M | $4.88M | $5.59M | $5.12M | $5.45M | $6.18M | $18.28M | $19.68M |
| Shareholders' equity | -$4.63M | -$3.52M | -$4.08M | -$2.96M | -$3.94M | -$3.84M | -$16.55M | -$15.95M |
| Net debt | $525,000 | $475,000 | $780,000 | $609,000 | — | — | $4.52M | $11.53M |
| Shares outstanding | 6.03M | 57.72M | 52.79M | 5.18M | 49.73M | 46.10M | 30.57M | 27.99M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.42M | -$1.88M | -$1.54M | -$1.71M | -$1.41M | -$2.19M | -$1.85M | -$2.03M |
| Capital expenditure | $1,000 | $9,000 | $2,000 | $5,000 | $0 | $3,000 | $5,000 | $35,000 |
| Free cash flow | -$1.42M | -$1.88M | -$1.54M | -$1.72M | -$1.41M | -$2.19M | -$1.86M | -$2.06M |
| Investing cash flow | -$1,000 | $56,000 | $352,000 | -$51,000 | $1.11M | -$670,000 | $1.92M | $365,000 |
| Financing cash flow | $1.20M | $1.94M | $838,000 | $2.20M | $331,000 | $3.03M | -$94,000 | -$100,000 |
| Depreciation & amortization | $8,000 | $5,000 | $11,000 | $9,000 | $10,000 | $34,000 | $12,000 | $26,000 |
| Stock-based compensation | $458,000 | $463,000 | $431,000 | $1.49M | $142,000 | $197,000 | $208,000 | $181,000 |
Free plan shows the latest 8 periods; Pro shows all 21 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.